Next Phase Newsletter

A private investment partnership based in the USA is dedicated to providing impact investment capital to life science and healthcare companies in both public and private markets. The firm can invest from $1 – 50M depending on the stage of development of the company. The firm is open to global opportunities and has expertise with working in global markets.

The firm is most interested in therapeutics opportunities, and medical devices to a lesser extent. The firm looks for technologies that have the potential to make a significant impact to the global population. In therapeutics, the firm can look as early as pre-clinical to Phase I/IIa. For devices, the firm looks for those that are close to 510k FDA approval.

The firm invests in both publicly traded and privately owned companies. The firm prefers to work with experienced, transparent management teams with clearly demonstrated growth and defined (or capable of helping define) exit strategy. The firm prefers to lead and requires a board of directors seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic investment firm based in the Netherlands with an additional operation in Boston, USA, is investing from a fund of over $250 million.  The firm prefers to invest in commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in London, UK that focuses exclusively on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is technology and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A group of globally acting venture capital and private equity firms with an operating track record of over 30 years manages multiple funds globally. The group’s Life Science Venture arm is looking to provide seed, venture and growth capital to companies in the life science space. The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is a dedicated provider of venture capital to the international pharmaceutical, medical technology and healthcare diagnostics industries, hence looking to invest in companies in sectors of Medical devices, Diagnostic Tools and Platforms, and Specialty Pharmaceuticals that are later stage with strong in human data (Phase IIb and III or on the market) and have very little regulatory risk. The firm’s most recent Life Science Venture Capital Fund is a venture capital fund registered in North America, which focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise. The firm is also less inclined to invest into orphan indications.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture arm of a bank has a €250M evergreen fund, with about half of their investments in the life sciences. The firm invests primarily during series A-B rounds, but will occasionally invest in seed-stage companies as well, and will follow on in subsequent rounds. The firm invests in medical device, diagnostics and digital health companies, and can invest throughout Europe, but focuses mostly in France. The firm will invest anywhere from €1-20M.

The firm invests in medical devices, diagnostics and digital health technologies. Generally, the firm does not invest in therapeutics companies, nor companies in clinical stages. The firm will usually not invest in companies before they have earned their CE mark, and is generally opportunistic to indication.

The firm will only lead or co-lead investments, and always takes a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taipei makes venture stage investments solely in life sciences companies. The firm is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 30% on foreign deals and is currently seeking new opportunities.

The firm is focused on pharmaceuticals, medical devices, diagnostic products, and medical instruments etc. The firm looks for companies with strong intellectual propositions that will develop unmet medical need products. The firm intends to explore joint venture opportunities with foreign companies that can integrate Taiwan’s competitive capabilities in manufacturing, clinical development, and regional sales/distribution.

The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with invested companies closely.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A major reinsurance firm based in Europe makes direct venture stage investments in strategically relevant healthcare startups through a corporate venture capital team, and also invests in life science funds and incubators around the world. The firm invests opportunistically, with a focus on early stage opportunities.

The firm invests strategically in startups that could potentially drive growth in its life and health insurance businesses. In life sciences, the firm is interested in the convergence of life science and insurance tech, and invests in areas such as genomics, digital health, and diagnostics (including diagnostic products focused on consumers as users). The firm is open to investing in any indication area.

The firm’s investments are strategic in nature, and the firm can potentially act as a strategic partner to a portfolio company by supporting product deployment among its network in the health insurance space.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.